Gemcitabine and vinorelbine in recurrent head and neck cancer: Pharmacokinetic and clinical results

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2845-2852

  Airoldi, Mario ^a   Cattel, Luigi ^b   Cortesina, Giorgio ^b   Giordano, Carlo ^b   Passera, Roberto ^b   Pedani, Fulvia ^b   Novello, Silvia ^b   Bumma, Cesare ^b   Gabriele, Pietro ^b  

^a MOLINETTE HOSPITAL   (Italy)

^b NONE

Author keywords

Chemotherapy; Gemcitabine; Head and neck cancer; Pharmacokinetic; Vinorelbine

Indexed keywords

GEMCITABINE; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG RESPONSE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SIDE EFFECT; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; VINBLASTINE;

EID: 0042123572     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Gebbia V, Testa A, Valenza R, Zerillo G, Restivo S, Ingria F, Cannata G and Gebbia N: A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29-A: 1358-1359 (letter), 1993.
2. Oliveira J, Geoffrois L, Rolland F, Degardin M, Armand JP, Boudillet J, Tresca P, Lentz MA, Vanglabbeke M and Fumoleau P: Activity of Navelbine on lesions with previously irradiated fields in patients with metastatic and/or local recurrent squamous cell carcinoma of the head and neck: an EORTC-ECSG study. Proc Am Soc Clin Oncol 16: 406 (abstr 1449), 1997.
3. Romanini A, Surbona A, Ricci S and Conte PF: Phase II of continuous infusion of vinorelbine in patients with locally pretreated advanced head and neck cancer. Proc Annu Meet Am Assoc Cancer Res 34: A1222 (abstr), 1993.
4. Canfield VA, Saxman SB, Kolodziej MA, Harrison-Mann B, Loehrer PJ and Vokes EE: Phase II trial of vinorelbine in advanced or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 16: 387 (abstr 1382), 1997.
5. Testolin A, Recher G, Cristoferi V and Gasparini G: Vinorelbine in pre-treated head and neck squamous cell carcinoma: a phase II study. Invest New Drugs 12: 231-234, 1994.
6. Gebbia V, Testa A, Di Gregorio G, Ingria F, Valenza R, Cannata G, Moschella F, Restivo G and Gebbia N: Vinorelbine plus cisplatin in recurrent or previously untreated unresectable metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 18: 293-296, 1995.
7. Catimel G, Caliandro R, Terret C, Dumortier A, Gignoux B, Leval F, Montbarbon X, Gourmet R and Droz FP: A phase II study of cisplatin and 96-hour continuous infusion of navelbine in patients with advanced squamous cell carcinoma of the head and neck. Eur J Cancer 3 (suppl 5): 94 (abstr 434), 1995.
8. Gebbia V, Testa A, Valenza R, Ferrero B, Giuffrè S, Carreca I and Gebbia N: Vinorelbine plus cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell head and neck cancer, Proc Am Soc Clin Oncol 12: 283 (abstr 917), 1993.
9. Rivera F, Lopez-Brea F, Lopez-Vega JM, Pascual C, Rubio A, Rama J, Perez-Lastra L and Sanz-Ortiz J: High activity of UFT, vinorelbine and cisplatin as induction chemotherapy for locally advanced squamous cell head and neck carcinoma. Proc Am Soc Clin Oncol 16: 386 (abstr 1376), 1997.
10. Gaspar C, Munoz MA, Yaya R, Soriano V, Climent MA and Guillem V: A phase II study of vinorelbine, cisplatin and 5-fluorouracil in patients with locally advanced recurrent, and or metastatic squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 18: 406 (abstract 1568), 1999.
11. Masci G, Chiesa F, Orecchia R, Calabrese L, Fossa-Jereckz B, Ansarin M, Gebbia V, Marrocco E, Nolè F, De Pas T, Ferretti G and de Braud F: Vinorelbine, continuous infusion 5-fluorouracil and cisplatin in patients with inoperable head and neck carcinoma. A regimen with a low toxicity profile. Proc Am Soc Clin Oncol 19: 432 (abstr 1694N), 2000.
12. Rivera F, Lopez-Brea M, Pascual C, De Juan A, Lopez-Vega JM, Sanz-Ortiz J, Isla D, Tres A, Rubio A and Rama J: Interim analysis of a phase III study of cisplatin and 5-FU continuous infusion vs cisplatin, UFT and vinorelbine as induction chemotherapy in locally advanced squamous cell head and neck cancer. Proc Am Soc Clin Oncol 18: 399 (ab.str 1542),1999.
13. Airoldi M, Bumma C, Bertetto O, Riella AM, Gabriele P, Succo G and Bussi M: Vinorelbine for recurrent adenocarcinoma-like salivary gland malignancies. Oral Oncol Eur J Cancer 32: 213-214 (letter), 1996.
14. Airoldi M, Bumma C, Bertetto O, Gabriele P, Succo G and Pedani F: Vinorelbine treatment of recurrent salivary gland carcinoma. Bull Cancer 85: 892-894, 1998.
15. Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S and Bumma C: Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91: 541-547, 2001.
16. Pan H, Lin C, Tasi M, Huang G, Huang W and Chen T: A pilot study of vinorelbine on a weekly schedule in metastatic nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 19: 427 (abstr 1689), 2000.
17. Samlowski W, Gundacker H, Kuebler JP, Giguere JK, Mills GM, Schuller DE and Ensley JF: Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group Phase II study. Invest New Drugs 19(4): 311-315, 2001.
18. Hitt R, Castellano D, Hidalgo M, Garcia-Carbonero R, Pena M, Brandariz A, Millan JM, Alvarez Vincent JJ and Cortes-Funes H: Phase II trial of cisplatin and gemcitabine in advanced squamous cell carcinoma of the head and neck. Ann Oncol 9(12): 1347-1349,1998.
19. Heinemann V, Hertel LW, Grendey GB and Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-B-D-arabinofuranosylcytosine. Cancer Res 48: 4024-31, 1998.
20. Zhou-Pan X, Sérée E, Zhou X-J, Placidi M, Maurel P, Barra Y and Rahmani R: Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 53: 5121-6, 1993.
21. Bouffard DY, Laliberté J and Momparler RL: Kinetic studies on 2′,2′-difluorodeoxycytidine with purified human deoxycytidine kinase and cytidine deaminase. Bioch Pharmacol 45(9): 1857-1861, 1993.
22. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42 (3): 155-99, 1990.
23. Yih-Gang Goan, Bingsen Zhou, Edward Hu, Shu Mi and Yun Yen: Overexpression of ribonucleotide reductase as a mechanism of resistance to 2′,2′-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59: 4204-4207, 1999.
24. Cattel L, Recalenda V, Airoldi M, Tagini V, Arpicco S, Brusa P and Bumma C: A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. Il Farmaco 56: 779-784, 2001.
25. Freeman KB, Anliker S, Hamilton M, Osborne D, Dhahir PH, Nelson R and Allerheiligen SRB: Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 665: 171-81, 1995.
26. Robieux I, Vitali V, Aita P and Freschi A: Sensitive high-performance liquid chromatographic method with fluorescence detection for measurement of vinorelbine plasma concentration. J Chromatogr B Biomed Appl 675: 183-187, 1996.
27. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W and Raber MN: A phase I clinical plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-8, 1991.
28. Johnson SA: Clinical pharmacokinetic of nucleoside analogues. Clin Pharmacokinet 39: 5-26, 2000.
29. Storniolo AM, Allerheiligen S and Pearce HL: Preclinical, pharmacologic and phase I studies of gemcitabine. Semin Oncol 24: 2-7, 1997.
30. Jehl F, Quoix E, Leveque D, Pauli G, Breillout F, Krikorian A and Monteil H: Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 51: 2071-3, 1991.
31. Sorio R, Robieux I, Galligioni E, Freschi A, Colussi AM, Crivellari D, Saracchini S and Monfardini S: Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 33: 301-3, 1997.
32. Campbell J, Dorman E, McCormick M, Miles J, Morton RP, Rugman F, Stell PM, Stoney PJ, Vaughan ED and Wilson JA: A randomised phase III trial of cis-platinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-fluorouracil in end stage head and neck cancer. Acta Otolaryngol 103: 519-528, 1987.
33. The Liverpool Head and Neck Oncology Group: A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61: 311-315, 1990.
34. Amer MH, Al-Sarraf M and Vaitkevicius VK: Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer 43: 2202-2206, 1979.
35. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng N, Dalton T, Burroughs and Rozencweig M: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263, 1992.
36. Al-Sarraf M: Cisplatin combinations of head and neck cancer. Semin Oncol 21 (suppl 12): 28-34, 1994.
37. Pivot X, Niyikiza C, Poissonnet G, Dassonville O, Bensadoun RJ, Guardiola E, Foa C, Benezery K, Demard F, Thyss A and Schneider M: Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trials. Oncology 61: 197-204, 2001.
38. Erjala K, Pulkkinen J, Kulmala J, Alanen K and Grenman R: Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in vivo Anticancer Res 22: 3135-3142, 2002
39. Airoldi M, Marchionatti S, Pedani F, Bumma C, Strada MR and Bernardo G: Docetaxel + Vinorelbine in recurrent heavily pre-treated head and neck cancer patients. Proc Am Soc Clin Oncol 18: 402 (abst 1554), 1999.